AP1189 Safety and Efficacy for Severe Respiratory Viral Infection
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Currently hospitalized with low oxygen levels (below 93% on room air) caused by confirmed respiratory virus infection (COVID-19, flu A/B, or RSV)
- Symptoms started fewer than 15 days before hospital admission
- Screened and enrolled within 24 hours of hospital arrival or transfer
- Not already on a breathing machine, ECMO, heart support medications, or dialysis
- If female and able to become pregnant: negative pregnancy test and using reliable contraception
- Willing to participate only in this trial (no other drug trials at the same time)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called AK0529 for babies and toddlers hospitalized with RSV. It aims to see if the drug helps them recover faster and is safe for this age group.
This trial studies whether giving antibiotics affects recovery in adults hospitalized with moderately severe infections caused by specific viruses (influenza, parainfluenza, RSV, or hMPV). It may help show when antibiotics are helpful or unnecessary for viral airway illness.
This study is testing different treatments for people with respiratory infections like the flu who are not in the hospital. You may be able to join if you have a positive test, have symptoms like cough or fever, and start within a few days of feeling sick.
This trial tests an experimental drug called S-337395 for adults with RSV who are not in the hospital but are at high risk for severe illness. It aims to see if the drug can help prevent symptoms from getting worse.
This trial tests if antiviral medications can help adults with early respiratory syncytial virus (RSV) feel better faster. It is for people aged 18 to 64 who have had RSV symptoms for 4 days or less and have tested positive for the virus.
This trial tests a drug called AVM0703 to see if it can help people with severe lung damage caused by COVID-19 or influenza. It focuses on patients who need a breathing machine or ECMO because their lungs are failing.
Hear when a new Respiratory Viral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.